4,901 trials
Healthy
Primary: Ratio of Cmax of BI 409306 in CSF Compared to Plasma — 0.267; 0.244; 0.294; 0.335 Ratio — p=1.0000
Prostate Cancer
Primary: Frequency of Dose-limiting Toxicity at Escalating Dose Levels of CTT1403 — 0; 0; 0; 0 Participants
Hepatic Impairment · Healthy Volunteers
Primary: Maximum Plasma Concentration (Cmax) — 23.56; 31.37; 51.82; 78.73 nanogram per milliliter (ng/mL)
ADHD
Primary: Non-displaceable Tracer Binding Potentials — 2.93; 2.91; 1.50; 1.50 ratio
Psychosis
Primary: Change From Baseline in Perceived Treatment Efficacy — 2.6; 1.6; 0.5; 0.5 score on a scale
Psoriasis
Primary: Percentage (%) of Participants Who Achieved Greater Than or Equal (>=) to 75% Improvement From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12 — 5; 0…
Cerebrovascular Stroke · Large-Artery Atherosclerosis (Embolus/Thrombosis) · Intracranial Arteriosclerosis
Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 1; 0; 1 Participants
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events in SRD Part — 0.0; 0.0; 0.0; 33.3 Percentage of participants
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events (AEs). — 50.0; 16.7; 66.7; 33.3 Percentage of participants
Chronic Obstructive Pulmonary Disease (COPD) · COPD
Primary: PK Parameter -- AUC(0-t_iv) -- Plasma -- [14^C] Total — 5.4025 h*ngEq/mL
Healthy
Primary: Area Under the Concentration-time Curve of BI 655130 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 1579.19; 2204.35…
Homeostasis · Bone and Bones
Primary: Percent Change From Baseline to Week 26 in Bone Formation Marker Aminoterminal Propeptide of Type 1 Collagen (P1NP) — -0.4; 19.3; 16.9 percent change
Healthy
Primary: Area Under the Concentration-time Curve of BI 655130 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) — 1227.91; 1150.18; 1718.47…
Fabry Disease
Primary: Maximum Serum Concentration of Agalsidase Beta (Cmax) — 95.51; 109.65 mU/ml
Healthy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 5; 3; 5; 6 Participants